Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Aug;27(8):e15308.
doi: 10.1111/1756-185X.15308.

The cardiovascular risk of JAK inhibitors in treating rheumatic diseases

Alexander Kwan  1 , Elvina Ingrid  1 , Matthew Jiang  1 , Keith K T Lim  1
Affiliations
Editorial

The cardiovascular risk of JAK inhibitors in treating rheumatic diseases

Alexander Kwan et al. Int J Rheum Dis. 2024 Aug.
No abstract available

Keywords: JAK inhibitor; baricitinib; cardiovascular risk; inflammatory arthritis; tofacitinib; upadacitinib.

PubMed Disclaimer

References

REFERENCES

    1. Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with Tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316‐326. doi:10.1056/NEJMoa2109927
    1. Kotyla PJ, Islam MA, Engelmann M. Clinical aspects of Janus kinase (JAK) inhibitors in the cardiovascular system in patients with rheumatoid arthritis. Int J Mol Sci. 2020;21(19):7390. doi:10.3390/ijms21197390
    1. Van Der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve‐month data from a twenty‐four‐month phase III randomized radiographic study. Arthritis Rheum. 2013;65(3):559‐570. doi:10.1002/art.37816
    1. Charles‐Schoeman C, Buch MH, Dougados M, et al. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL surveillance. Ann Rheum Dis. 2023;82(1):119‐129. doi:10.1136/ard-2022-222259
    1. Toussirot E. The interrelations between biological and targeted synthetic agents used in inflammatory joint diseases, and obesity or body composition. Metabolites. 2020;10(3):107. doi:10.3390/metabo10030107

Publication types

MeSH terms

Substances

LinkOut - more resources